
TCR-focused Immatics adds another marquee name to its list of partners: GSK
Immatics, in its fecund deal spree, has lured GSK, as the British drugmaker refocuses its attention to the lucrative field of oncology.
On Thursday, the privately-held immuno-oncology company secured $50 million upfront in a collaboration with GSK on two T cell receptor (TCR) therapeutics focused on solid tumors. If all goes well, Immatics stands to earn more than $550 million in milestone payments, in addition to tiered royalties for each product.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.